Endocrine Abstracts

Introduction: Studies investigating the association between serum IGF-1, and thyroid nodule, ovarian or thyroid volume in polycystic ovarian syndrome (PCOS) are limited. We aimed to analyze the association between serum IGF-1 level, and ovarian or thyroid volume, or thyroid nodule in PCOS.

Materials and methods: The study was performed between June 2017 and August 2019 as prospective design. The patients referred to our medical faculty were included. Adult females with new-onset PCOS were included. The patients having comorbid illness, or using medication were excluded. Basic laboratory tests, thyroid and ovarian sonography were performed. The patients were grouped according to thyroid nodule (absent/present) and ovarian volume (<10 ml/ ≥10 ml). We planned to find a positive association between IGF-1, and thyroid nodule, thyroid or ovarian volume in PCOS.

Results: Of total 118 patients, 11 (9%) had thyroid nodule. The patients with thyroid nodule had a higher thyroid and ovarian volume (P = 0.026, P = 0.006; respectively). No correlation was found between GH or IGF-1, and thyroid or ovarian volume. IGF-1 was not a predictor for thyroid nodule or higher ovarian volume. The higher DHEAS and thyroid nodule were found as significant predictor for higher ovarian volume.

Conclusions: To our knowledge, our study is the first to analyze the association between IGF-1 and thyroid nodule in PCOS. We found that thyroid nodule was associated with thyroid and ovarian volume, but IGF-1 was not associated with thyroid nodule, thyroid or ovarian volume. It should be kept in mind that metabolic screening is essential but we do not recommend routine measurement of IGF-1 in PCOS.